Biolife Solutions to acquire Repligen Corp

Biolife Solutions announced a definitive agreement to acquire Repligen Corp in a cash and stock transaction valued at approximately $3.55 billion. This strategic M&A deal expands Biolife's capabilities in cell and gene therapy manufacturing.